Investing

The U.S. government on Friday approved the formation of a new Silicon Valley stock exchange following a regulatory criticism late last year. Backed by top Valley figures such as venture capitalist Marc Andreessen, the Long-Term Stock Exchange was born out of concern from the nation’s tech elite who were frustrated that the public market’s focus
0 Comments
Tesla‘s increasing production rate and active resale market may be hurting the brand’s appeal and diminish demand for its cars, Morgan Stanley said on Friday, in a counter-intuitive note to clients. “Many auto companies make great efforts to maintain and remarket their used vehicles to increase accessibility of the used product to customers who otherwise
0 Comments
SoftBank is launching a second $100 billion tech fund: Vision Fund II, the company’s chief said Thursday. “This is the first time that they’re officially announcing that we would like to start preparing for the establishment of the SoftBank Vision Fund II,” SoftBank chief Masayoshi Son said on the company’s earnings call. Son said the
0 Comments
Two prominent market voices squared off Wednesday over the future of cryptocurrencies in a debate that ended with a bet over a T-shirt. Economist Nouriel Roubini, who for many years wore the sobriquet “Dr. Doom,” said bitcoin and its peers don’t even deserve to be called “cryptocurrencies.” Investor and former hedge fund manager Michael Novogratz
0 Comments
Glenview Capital Management CEO Larry Robbins said Monday that he’s shorting shares of industrial conglomerate 3M. Robbins underscored 3M’s mounting litigation headaches, which span multiple states and center on pollution as a result of its operations. The manager added that, since 2015, 3M’s lawsuits have soared 87 fold and now pose a significant liability to
0 Comments
Adam Jeffery | CNBC Bihua Chen, founder and portfolio manager at Cormorant Asset Management, said on Monday she likes kidney disease drug maker Reata Pharmaceuticals. The kidney drug that Reata is developing called Bardoxolone has “striking efficacy,” the hedge fund manager said from the Sohn Conference in New York. Shares of Reata Pharmaceutical jumped more
0 Comments